A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer

Diseases and Conditions Researched


What is the purpose of this trial?

The objectives of this study are to assess the safety, pharmacokinetics, immunogenicity and anti-tumor activity of AGS15E in subjects with metastatic urothelial cancer who failed at least one prior chemotherapy regimen for metastatic disease.

Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Agensys, Inc.
Last Updated:
Study HIC#: 1307012407